Skip to main content

Table 2 The difference of related variables between non-relapsed and relapsed groups

From: Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders

Variable Non-relapsed (n = 20) Relapsed (n = 12) Mean Difference Std. Error Difference p-value
Age of onset, year 33.35 33.16 −0.183 4.740 0.969
Mean BMI 23.89 24.63 0.741 1.415 0.604
Disease duration, months 80.40 94.17 13.77 25.81 0.589
Duration of AZA therapy, months 22.10 20.50 −1.6 2.278 0.488
Mean CSF protein, mg/dl 39.82 41.43 1.613 13.275 0.904
Mean Concentration of CSF IgG, mg/ml 0.040 0.032 −0.008 0.014 0.577
CSF IgG index (n%) 0.546 0.494 −0.519 0.039 0.199
Serum anti-AQP4 antibodies (n%) 10 (50%) 4 (33.3%) / / 0.471
Pre-therapy EDSS score 5.17 5.29 / / 0.687
Post- therapy EDSS score 2.43 2.83 / / 0.893
Normalized concentration of 6-TGNs 1.12 0.70 −0.418 0.09 <0.0001*
Normalized concentration of 6-MMPNs 10.60 3.62 −6.983 2.32 0.006*
  1. NMOSD, AZA Azathioprine, BMI Body mass index, ARR Annual relapse rate, AQP4 anti-aquaporin 4, EDSS Expanded disability status scale, 6-TGN 6-thioguanine nucleotides, 6-MMPN 6-methylmercaptopurine nucleotides, CSF cerebrospinal fluid, IgG Immunoglobulin G. All two-tailed P-value <0.05 was considered statistically significant
\